CHARLESTON, SC – Efferent Labs®, a vanguard in biotechnological innovation, today announced a significant expansion of its intellectual property portfolio, reinforcing its leadership status in the biotech industry. The company…

(BUFFALO, NY) Apr. 1, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in vivo cellular data, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Trademark No. 6,687.149…

(BUFFALO, NY) Feb. 15, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in vivo cellular data, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,246,486…

(CHARLESTON, S.C.) Mar 6, 2021/GlobeNewswire/ – Today, Efferent Labs announces an expanded development collaboration with W. L. Gore & Associates, Inc. (Gore) to explore the utility of Gore’s technology in…

(CHARLESTON, S.C.) Aug. 18, 2020 /PRNewswire/  Efferent Labs and W. L. Gore & Associates (Gore) today announced a collaboration to explore implantable biosensing for long-term chronic disease management. In part, Gore will…

(Rochester, NY) Nov 14, 2018 Efferent Labs,, Inc. is proud to have won a position in the second cohort of Luminate. Empire State Development (ESD) announced the companies selected to…

(BUFFALO, NY) September 3, 2019 – Efferent Labs, Inc., a developer of high-value medical technology and devices, is pleased to announce its relocation to a state-of-the-art facility in Buffalo, NY on September…

(San Jose, CA) Nov 5, 2019 Efferent Labs, Inc. is proud to announce the winning of Gore Biosensing Startup Pitch Competition at Gore Advanced Materials Innovation Day in Silicon Valley.…

(Charleston, SC) November 14, 2019 Efferent Labs won the Charleston Angel Conference 2019 Pitch Contest. The Win brings along with it a six figure investment from CAC2019. The Charleston Angel…